75 related articles for article (PubMed ID: 12478886)
1. [Chemotactic peptide fMLP enhances antitumor activity of boanmycin].
Li ZD; Li Y; Zhen YS
Ai Zheng; 2002 Aug; 21(8):828-32. PubMed ID: 12478886
[TBL] [Abstract][Full Text] [Related]
2. [Minocycline potentiates the antimetastatic effect of boanmycin].
Liu JG; Jiang M; Xu LN; Zhen YS
Yao Xue Xue Bao; 1995; 30(9):668-73. PubMed ID: 8701742
[TBL] [Abstract][Full Text] [Related]
3. The main functions and structural modifications of tripeptide N-formyl-methionyl-leucyl-phenylalanine (fMLP) as a chemotactic factor.
Yang KH; Fang H; Ye JS; Gong JZ; Wang JT; Xu WF
Pharmazie; 2008 Nov; 63(11):779-83. PubMed ID: 19069235
[TBL] [Abstract][Full Text] [Related]
4. In vitro activation of tumoricidal properties in mouse macrophages using the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP) incorporated in liposomes.
Morikawa K; Nayar R; Fidler IJ
Cancer Immunol Immunother; 1988; 27(1):1-6. PubMed ID: 3396025
[TBL] [Abstract][Full Text] [Related]
5. Deactivation of guinea pig pulmonary alveolar macrophage responses to N-formyl-methionyl-leucyl-phenylalanine: chemotaxis, superoxide generation, and binding.
Daughaday CC; Mehta J; Spilberg I; Atkinson JP
J Immunol; 1985 Mar; 134(3):1823-6. PubMed ID: 2981922
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of macrophage invasion of tumors by administration of chemotactic factor-antitumor antibody conjugates.
Obrist R; Sandberg AL
Cell Immunol; 1983 Oct; 81(1):169-74. PubMed ID: 6651932
[TBL] [Abstract][Full Text] [Related]
7. Differential inhibition of human neutrophil activation by cyclosporins A, D, and H. Cyclosporin H is a potent and effective inhibitor of formyl peptide-induced superoxide formation.
Wenzel-Seifert K; Grünbaum L; Seifert R
J Immunol; 1991 Sep; 147(6):1940-6. PubMed ID: 1653806
[TBL] [Abstract][Full Text] [Related]
8. [Inhibitory effect of boanmycin on the growth of colon carcinoma 26 and hepatic metastasis in mice].
Liu XJ; Li Y; Zhen YS
Yao Xue Xue Bao; 2001 Jan; 36(1):14-8. PubMed ID: 12579853
[TBL] [Abstract][Full Text] [Related]
9. Temporal adaptation of neutrophil oxidative responsiveness to n-formyl-methionyl-leucyl-phenylalanine. Acceleration by granulocyte-macrophage colony stimulating factor.
English D; Broxmeyer HE; Gabig TG; Akard LP; Williams DE; Hoffman R
J Immunol; 1988 Oct; 141(7):2400-6. PubMed ID: 3049807
[TBL] [Abstract][Full Text] [Related]
10. Human neutrophil Fc gamma RIIIB and formyl peptide receptors are functionally linked during formyl-methionyl-leucyl-phenylalanine-induced chemotaxis.
Kew RR; Grimaldi CM; Furie MB; Fleit HB
J Immunol; 1992 Aug; 149(3):989-97. PubMed ID: 1321856
[TBL] [Abstract][Full Text] [Related]
11. Activation of macrophages with N-formyl-methionyl-leucyl-phenylalanine: involvement of protein kinase C and tyrosine kinase.
Shrivastava A
Indian J Exp Biol; 2007 Sep; 45(9):755-63. PubMed ID: 17907740
[TBL] [Abstract][Full Text] [Related]
12. Human monocyte adherence: a primary effect of chemotactic factors on the monocyte to stimulate adherence to human endothelium.
Doherty DE; Haslett C; Tonnesen MG; Henson PM
J Immunol; 1987 Mar; 138(6):1762-71. PubMed ID: 3819394
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of PGE1-induced increase in cyclic AMP by chemotactic peptide and Ca2+ ionophore through calmodulin-dependent processes.
Ishitoya J; Takenawa T
J Immunol; 1987 Feb; 138(4):1201-7. PubMed ID: 2433345
[TBL] [Abstract][Full Text] [Related]
14. Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils.
Nagano C; Azuma A; Ishiyama H; Sekiguchi K; Imagawa K; Kikuchi M
J Pharmacol Exp Ther; 2001 Apr; 297(1):388-94. PubMed ID: 11259567
[TBL] [Abstract][Full Text] [Related]
15. Binding of formyl peptides to Walker 256 carcinosarcoma cells and the chemotactic response of these cells.
Rayner DC; Orr FW; Shiu RP
Cancer Res; 1985 May; 45(5):2288-93. PubMed ID: 3986773
[TBL] [Abstract][Full Text] [Related]
16. The mechanism underlying the contractile effect of a chemotactic peptide, formyl-Met-Leu-Phe on the guinea-pig Taenia coli.
Kawata H; Hirano K; Nishimura J; Kubo C; Kanaide H
Br J Pharmacol; 2005 Jun; 145(3):353-63. PubMed ID: 15735654
[TBL] [Abstract][Full Text] [Related]
17. In vivo chemotaxis of rat leucocytes to N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP).
Onyia KA
Comp Immunol Microbiol Infect Dis; 1987; 10(1):33-9. PubMed ID: 3581774
[TBL] [Abstract][Full Text] [Related]
18. Characterization of liposomes containing the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP) and their interaction with mouse macrophages.
Nayar R; Morikawa K; Fidler IJ
Cancer Drug Deliv; 1987; 4(4):233-44. PubMed ID: 3454250
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil chemotactic heterogeneity to N-formyl-methionyl-leucyl-phenylalanine detected by the under-agarose assay.
Quitt M; Torres M; McGuire W; Beyer L; Coates TD
J Lab Clin Med; 1990 Feb; 115(2):159-64. PubMed ID: 2299263
[TBL] [Abstract][Full Text] [Related]
20. Chemotactic peptide enhancement of PMA triggered monocyte cytotoxicity.
Dallegri F; Patrone F; Ballestrero A; Frumento G; Sacchetti C
Clin Exp Immunol; 1984 Sep; 57(3):717-21. PubMed ID: 6467686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
